{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-22-000039","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.764705+00:00","generated_at":"2026-06-24T04:33:34.554379+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amgen Q2 2022: GAAP EPS $2.45, revenue $6.6B; guidance updated; non-GAAP policy change","bullets":["Total revenues $6.6B (+1% YoY); product sales +3% driven by Repatha, Prolia, LUMAKRAS, EVENITY.","GAAP EPS $2.45 vs $0.81 YoY; non-GAAP EPS $4.65 vs $1.77 YoY; free cash flow $1.7B flat.","2022 revenue guidance revised to $25.5-$26.4B; non-GAAP EPS reaffirmed $17-$18.","Updated non-GAAP policy excludes upfront/milestone payments; prior 2021 non-GAAP EPS recast to $13.92 from $17.10."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-22-000039","json":"https://secwatch.observer/filing/0000318154-22-000039.json","markdown":"https://secwatch.observer/filing/0000318154-22-000039.md","text":"https://secwatch.observer/filing/0000318154-22-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815422000039/0000318154-22-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815422000039/amgn-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:33:34.554379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}